Zeitschrift für Gastroenterologie, Table of Contents Z Gastroenterol 2001; 39(1): 33-38DOI: 10.1055/s-2001-10696 Leitlinien der DGVS © Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York Akuter Schub W. E Fleig Halle/Saale Recommend Article Abstract Buy Article Full Text References Literatur 1 Truelove S, Witts L. Cortisone in ulcerative colitis. Final report on therapeutic trial. BMJ. 1955; 2 1041-1048 (I b) 2 Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ. 1989; 298 82-86 (I b) 3 Beck I T. Laboratory assessment of inflammatory bowel disease. Dig Dis Sci. 1987; 32 26S-41S (III) 4 Schwerk W B, Beckh K, Raith M. A prospective evaluation of high resolution US in the diagnosis of inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1992; 4 173-182 (III) 5 Wijers O B, Tio T L, Tytgat G NJ. Ultrasonography and endosonography in the diagnosis and management of inflammatory bowel disease. Endoscopy. 1992; 24 559-564 (III) 6 Walmsley R S, Ayres R C, Pounder R E. et al . A simple clinical colitis activity index. GUT. 1998; 43 29-32 (III) 7 Travis S P, Farrant J M, Ricketts C. et al . Predicting outcome in severe ulcerative colitis. GUT. 1996; 38 905-910 (III) 8 Hyde G M, Jewell D P. Review article: The management of severe ulcerative colitis. Aliment Pharmacol Ther. 1997; 11 419-424 (IV) 9 Carbonnel F, Lavergne A, Lemann M. et al . Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci. 1994; 39 1550-1557 (III) 10 Bayerdörffer E, Höchter-Kühner W, Ottenjann R W. Bioptische Mikrobiologie und Enterokolitis. Dtsch Med Wochenschr. 1986; 111 796-798 (III) 11 Gionchetti P, Rizzello F, Venturi A. et al . Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998; 41 93-97 (I b) 12 Campieri M, Gionchetti P, Belluzzi A. et al . 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis?. J Clin Gastroenterol. 1988; 10 406-409 (I b) 13 Campieri M, Gionchetti P, Belluzzi A. et al . Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis. Dig Dis Sci. 1987; 32 67S-70S (I b) 14 Danish 5-ASA Group . Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Dig Dis Sci. 1987; 598-602 (I b) 15 Marshall J K, Irvine E J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: A meta-analysis. GUT. 1997; 40 775-781 (I a) 16 Lee F I, Jewell D P, Mani V. et al . A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. GUT. 1996; 38 229-233 (I b) 17 Safdi M, DeMicco M, Sninsky C. et al . A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997; 10 1867-1871 (I b) 18 Campieri M, Gionchetti P, Belluzzi A. et al . Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. GUT. 1991; 32 929-931 (I b) 19 Hanauer S B. Dose-ranging study of mesalamine enemas in the treatment of acute ulcerative proctosigmoiditis: Results of a multicentered placebo-controlled trial. Inflamm Bowel Dis. 1998; 4 79-83 (I b) 20 Danielsson A, Hellers G, Lyrenas E. et al . A controlled randomised trial of budesonid versus prednisolon retention enemas in active distal ulcerative colitis. Scand J Gastroenterol. 1987; 22 987-992 (I b) 21 Danielsson A, Lofberg R, Persson T. et al . A steroid enema, budesonid, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol. 1992; 27 9-12 (I b) 22 Lofberg R, Ostergaard O Thomsen, Langholz E. et al . Budesonid versus prednisolon retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther. 1994; 8 623-629 (I b) 23 Mulder C JJ, Fockens P, Meijer J WR. et al . Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2g) versus the combination of both (3 mg/2 g) as retention enema in active ulcerative proctitis. Eur J Gastroenterol Hepatol. 1996; 8 549-553 (I b) 24 Breuer R I, Soergel K H, Lashner B A. et al . Short-chain fatty acid rectal irrigation for left sided ulcerative colitis. Gut. 1997; 40 485-491 (I b) 25 Steinhart A H, Hiruki T, Brzezinski A, Baker J P. Treatment of left sided ulcerative colitis with butyrate enemas: A controlled trial. Aliment Pharmacol Ther. 1996; 10 729-736 (I b) 26 Lofberg R, Danielsson A, Suhr O. et al . Oral budesonide versus prednisolon in patients with active extensive and left-sided ulcerative colitis. Gastroenterology. 1996; 110 1713-1718 (I b) 27 Margolin M L, Krumholz M P, Fochios S TE. et al . Clinical trials in ulcerative colitis: II. Historical review. Am J Gastroenterol. 1988; 83 227-243 28 Sninsky C A, Cort D H, Shanahan F. et al . Oral mesalamine for mildly to moderatly active ulcerative colitis. A multicenter study. Ann Intern Med. 1991; 115 350-355 (I b) 29 Meyers S, Sachar D B, Present D H. et al . Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomised, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology. 1987; 93 1255-1262 (I b) 30 Feuerle G E, Theuer D, Velasco S. et al . Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: A randomised double blind trial. Gut. 1989; 30 1354-1361 (I b) 31 Hanauer S, Schwartz J, Robinson M. et al . Mesalamine capsules for treatment of active ulcerative Colitis: Results of a controlled trial. Am J Gastroenterol. 1993; 88 1188-1197 (I b) 32 Schroeder K W, Tremaine WJ, Ilstrup D M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317 1625-1629 (I b) 33 Kruis W, Brandes J W, Schreiber S. et al . Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther. 1998; 12 707-715 (I b) 34 Rachmilewitz D. Coated mesalazine versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989; 298 82-86 (I b) 35 Green J RB, Lobo A J, Holdsworth C D. et al . Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology. 1998; 114 15-22 (I b) 36 Levine D S, Pruitt R, Riff D. et al . A multicenter double-blind dose-response trial of colazide and asacol for mild-moderately active ulcerative colitis. Gastroenterology. 1997; 112 A1026 (I b) 37 Sutherland L R, May G R, Shaffer E A. Sulfasalazine revisited: A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med. 1993; 118 540-549 (I a) 38 Thomas G A, Rhodes J, Ragunath K. et al . Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis. Eur J Gastroenterol Hepatol. 1996; 8 769-776 (I b) 39 Oshitani N, Kitano A, Matsumoto T. et al . Corticosteroids for the management of ulcerative colitis. J Gastroenterol. 1995; Suppl. 8 118-120 (I b) 40 Meyers S, Lerer P K, Feuer E J. et al . Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomised, double-blind clinical trial. J Clin Gastroenterol. 1987; 9 50-54 (I b) 41 Evans R C, Wong V S, Morris A I. et al . Treatment of corticosteroid-resistent ulcerative colitis with heparin - a report of 16 cases. Aliment Pharmacol Ther. 1997; 11 1037-1040 (II b) 42 Folwaczny C, Wiebecke B, Loeschke K. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol. 1999; 94 1551-1555 (II b) 43 Evans R C, Clarke L, Heath P. et al . Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther. 1997; 11 1031-1035 (II b)
